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Abstract  
Competitive inhibitors of the influenza neuraminidase (NA) were discovered almost 20 years 
ago, with zanamivir and oseltamivir licensed globally. These compounds are based on a 
transition state analogue of the sialic acid substrate. We recently showed that 5-(Acetylamino)-
2,3,5-trideoxy-2,3-difluoro-D-erythro-β-L-manno-2-nonulopyranosonic acid (DFSA) and its 
derivatives are also potent inhibitors of the influenza NA. They are mechanism based inhibitors, 
forming a covalent bond between the C2 of the sugar ring and Y406 in the NA active site, thus 
inactivating the enzyme. We have now synthesized a series of deoxygenated DFSA derivatives 
in order to understand the contribution of each hydroxyl in DFSA to binding and inhibition of the 
influenza NA. We have investigated their relative efficacy in enzyme assays in vitro, in cell 
culture and by X-ray crystallography. We found loss of the 8- and 9-OH had the biggest impact 
on the affinity of binding and antiviral potency. 
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1. Introduction 
There are two types of influenza which cause significant morbidity and mortality in humans, 
influenza A and B. Both influenza A and B viruses have two surface glycoproteins, the 
hemagglutinin (HA) responsible for binding to sialic acid containing receptors on the cell 
surface, and the neuraminidase (NA) enzyme which is responsible for cleavage of sialic acids 
from the cell surface, to facilitate the spread of progeny virions. Influenza A is further divided 
into subtypes depending on the HA (18 subtypes) and NA (11 subtypes).  Two influenza A 
subtypes are endemic in humans, (H1N1) and (H3N2). Zoonotic transmission may occasionally 
occur from birds and swine, including the highly pathogenic avian (H5N1) and (H7N9) viruses 
and the A(H1N1)pdm09 pandemic swine virus.  
There are 9 residues in the NA active site which are highly conserved across all influenza A and 
B and which interact directly with substrate. These in turn are stabilized by a second shell of 10-
11 highly conserved residues, primarily by an extensive network of hydrogen bonds.1-4  These 
are defined as framework as they make no direct contact with the substrate but hold the 
functional residues in place for binding and catalysis. 
There are now four drugs which target the NA, neuraminidase inhibitors (NAIs), which due to 
the high conservation of the NA active site are effective against all strains of influenza. Four 
NAIs are licensed in various parts of the world for the treatment and prevention of influenza, 
oseltamivir, zanamivir (1) (Figure 1), peramivir and laninamivir,5 a long acting derivative of 
zanamivir. By inhibiting the influenza NA they prevent virus release, resulting in aggregation of 
viruses at the cell surface.6 Because of differences in the chemistry of the NAIs and subtle 
differences in NA structures they can bind with a different affinity to the same subtype. e.g. 
oseltamivir has lower IC50s than zanamivir for N2 NAs, whereas zanamivir has lower IC50s than 
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oseltamivir for N1 and influenza B NAs5, 7. Additionally, due to these differences, resistance can 
be both NAI and subtype specific.5, 7  While mutations conferring resistance are primarily in 
active site residues, mutations remote from the active site can also confer resistance.5 Thus, in 
developing novel NAIs they need to be evaluated against different influenza types and subtypes 
and against different known resistant mutants of influenza. 
We recently demonstrated that the difluorosialic acid (DFSA) mechanism based inhibitor 5-
(Acetylamino)-2,3,5-trideoxy-2,3-difluoro-D-erythro-β-L-manno-2-nonulopyranosonic acid (2) 
(Figure 1) and its C-4 amino- and guanidino- derivatives, could inhibit the NA enzyme activity 
and replication of influenza viruses both in vitro and in vivo.8 We showed by X-ray 
crystallography that 2 leads to inactivation of enzyme activity by the formation of a covalent 
bond between the C-2 of the sugar ring and the hydroxyl group of Y406 in the influenza enzyme 
active site. This covalently linked sialosyl-enzyme intermediate was trapped along with a 
transition-state analogue resembling an oxocarbenium ion.9 Also, the secondary non-catalytic, 
receptor binding site was occupied by DFSA in the influenza N9 NA–DFSA complex.  
In addition to the 4-amino and 4-guanidino derivatives of 2, we have now synthesized a series of 
deoxygenated DFSA derivatives 3–6 (Figure 1) in order to understand the contribution of each 
hydroxyl in binding and inhibition of these sialic acid based inhibitors to the influenza NA.10  
The influenza strains selected for evaluating the impact of removal of the OH groups were those 
of clinical importance to humans, including the endemic human strains seasonal A(H1N1), 
pandemic (H1N1)pdm09, A(H3N2) and B, and avian A(H5N1) and the A(H1N9) reassortant, as 
a model for the avian A(H7N9) NA. NAI resistant mutants of some of these viruses, with 
different resistance profiles, were also used in the enzyme assays. Some of these were previously 
tested against other DFSA inhibitors8 and interestingly not all mutants were resistant to the 
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DFSA inhibitors. Among the resistant viruses tested, the impacts of the amino acid substitutions 
on sensitivity to the known NAIs are as follows: D197E in influenza B NA affects binding of all 
sialic acid derived NAIs, due to altered interactions of the N-acetyl group on the ring with 
R152,11 H274Y in N1 NAs affects rotation of E276 necessary for binding the pentyl ether side 
chain of oseltamivir12 with only a small impact on binding of zanamivir, E119V in N2 NAs 
affects interactions of the 4-amino group on oseltamivir with the active site, E119G in N9 NAs 
specifically confers resistance to zanamivir, due to changes in the solvent structure and altered 
interactions of G119 with the 4-guanidino group.13 An H252Y substitution between avian 
(H5N1) clade 1 and 2 viruses leads to reduced oseltamivir sensitivity.14  
The NAIs oseltamivir and 1 are competitive inhibitors and a fluorescence based enzyme 
inhibition assay is routinely used for evaluating the sensitivity of influenza virus NAs in vitro.7, 
15-17 However, normally only a single IC50 value is calculated after 30-60 min.
7, 17 While a single 
IC50 value provides details on the relative affinity of these NAIs it does not provide any 
information on the relative rates of drug binding. As compound 1 is a competitive inhibitor, its 
efficacy is strongly reflected by its affinity (IC50) for the NA. However, since compounds 2-6 are 
mechanism based inhibitors,8 their efficacy is dependent not only on the affinity, but upon both 
the rate of inactivation, (dependent on both the Michaelis complex formation as well as the 
subsequent covalent bond formation), and the rate of reactivation (breakdown of the covalent 
intermediate followed by dissociation of the product). Kinetic analyses of inhibitor binding and 
dissociation requires large amounts of purified enzyme/virus and are labour intensive,8, 18 
limiting the numbers of virus/inhibitor combinations that can be readily assayed. 
We have developed two microtiter fluorescence based enzyme inhibition assays which use 
unpurified virus, and instead of taking a single reading, monitor the reactions in real time.  The 
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IC50 kinetics assay monitors the changes in IC50 values for each 10 min over 60 min, in two 
separate reactions with and without pre-incubation. This provides information on not only 
relative affinity (IC50), but the relative rates of binding and dissociation of each of the 
compounds16, 19 A solid phase reactivation assay monitors the time to recover activity after 
removal of inhibitor over several hours.19 We have previously used these assays to demonstrate 
slow binding kinetics and rates of dissociation of the NAIs consistent with those observed using 
purified NA in the classic assays.16, 19-22 Additionally, we have shown that while wild type 
viruses generally demonstrate slow binding of the known NAIs, the NAs of resistant mutants 
demonstrate rapid binding and dissociation of the NAIs.11, 15, 16, 19, 23, 24  
We have used these assays here to compare relative inhibition of the NAs of a large panel of wild 
type and drug resistant mutants by each of the deoxy derivatives 3-6. For the sake of simplicity, 
we will refer to inactivation as binding and reactivation as dissociation as we are also comparing 
them to the binding and dissociation of competitive NAIs. 
In addition, we have evaluated the efficacy of 3-6 to inhibit replication of wild type viruses in 
cell culture in a plaque reduction assay. We show that loss of the 8- and 9-OH have the biggest 
impact on the affinity of binding and antiviral potency both in vitro and in cell culture. 
We have also used structural analysis by X-ray crystallography of the N9 NA in complex with 
each of the inhibitors, to help explain the biological impact of the removal of the OH groups on 
binding. While we have used the G70C (H1N9) virus as a model virus and its NA for structural 
studies for many years, the N9 subtype has become more relevant due to the emergence of a 
highly lethal (H7N9) virus in China.25, 26 
 
2. Results 
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2.1 IC50 Kinetics 
Compounds 1-6 were all evaluated in the microtiter based IC50 kinetics assays against each of the 
wild type and mutant viruses in the panel. IC50 values for each time point were calculated as the 
concentration of inhibitor which reduced the NA enzyme activity by 50% compared to the 
control uninhibited enzyme activity. We used zanamivir as a reference for a slow binding 
inhibitor with high affinity.16 The greater the difference in final (60 min) IC50 values between the 
reactions without and with preincubation (-/+ ratio), the slower the binding (Figures 2 and 3, 
Table 1). We have previously shown for the NAIs that fast binding inhibitors have a -/+ ratio of 
around 1 for the 60 min IC50 values, and slower binding inhibitors have ratios of >1.5-2, 
indicating that preincubation enhances binding. Additionally, the rate of increase of the IC50 
values after preincubation with inhibitor upon addition of MUNANA substrate, gives a 
qualitative indication of the dissociation rate. The faster the increase, i.e. the greater the 
difference between the 10 min and 60 min IC50 values, the faster the dissociation. A lower ratio 
indicates slower dissociation (Figures 2 and 3, Supporting information Table S1).  All assays 
were carried out in duplicate as described in the Experimental section. The IC50 value for each 10 
min time point is the mean of the individual IC50 values of the duplicates for that virus-inhibitor 
reaction. The profiles of the bar graphs (Figures 2 and 3) provide an easy overview of changes in 
IC50 values for the large number of virus and compound combinations, showing whether the IC50 
values increase or decrease with and without preincubation over the 60 min reaction time, 
indicative of fast or slow binding/dissociation. Comparisons of the 60 min IC50 values without 
and with preincubation, as an indication of relative slow or fast binding are all presented in Table 
1. Comparisons of the change in IC50 values between 10 and 60 min, as an indication of the 
relative dissociation rate, are all presented in Supporting information, Table S1. 
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2.1.1 N1 NAs 
The compounds were tested against the seasonal (H1N1) and H274Y oseltamivir resistant 
viruses, swine and human isolates of (H1N1)pdm09 viruses, and two avian (H5N1) viruses, 
which differ in oseltamivir sensitivity. None of the inhibitors showed the classic slow binding 
profile of the bar graphs seen with zanamivir (1), where the IC50 values continue to decrease 
without preincubation from 10 to 60 min, and are significantly lower after preincubation (Figure 
2, Table 1).  
Despite large sequence differences between the (H1N1)pdm09 and (H5N1) NAs their kinetics 
profiles were very similar for each of the inhibitors (Figures 2B, 2C), but both were different to 
the seasonal (H1N1) NA and its H274Y mutant (Figure 2A). Consistent with previous findings, 
clade 1 (H5N1) NA showed faster dissociation of 1 than clade 2 NA16, 19 (Figure 2C and 
Supporting information Table S1).  
IC50 kinetics profiles for compounds 2 and 3 were similar to those previously seen with NAI 
resistant mutant NAs.16 They showed fast binding/dissociation to both the (H1N1)pdm09 and 
(H5N1) NAs, with similar IC50 values with or without preincubation. In contrast, 2 demonstrated 
slow binding to the seasonal (H1N1) NA, while the loss of 4-OH increased both the affinity and 
rate of binding for compound 3 (Figure 2 and Table 1). 
Removal of the 7-OH resulted in slightly higher affinity of 4 for the wild type seasonal (H1N1) 
NA and slow binding. As seen with 2, loss of the 7-OH resulted in reduced affinity to the H274Y 
mutant NA. However, unlike previous mutant NAs, it had different binding kinetics. The IC50 
values were similar with or without preincubation, but continued to decrease in both reactions. 
Rather than fast binding this indicated slower binding/dissociation (Figure 2A, Table 1, 
Supporting information Table S2). 
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Loss of the 8-OH resulted in compound 5 binding with a much lower affinity to all the N1 NAs 
compared to compounds 2, 3 or 4. Kinetics showed an unusual pattern of binding to the 
(H1N1)pdm09 and clade 2 (H5N1) NAs, where the IC50 values were not significantly different 
with or without preincubation, however they continued to decrease after the addition of substrate 
(Figure 2B, C). We have not previously observed this with other NAIs binding to wild type NAs, 
but it suggested there was slower turnover, possibly because of both slow binding and slow 
dissociation. In contrast, there was an increase in IC50 values for the clade 1 (H5N1) NA after 
preincubation with 5, indicating a faster dissociation (Figure 2C, Supporting information Table 
S1). 
Loss of the 9-OH also had a significant impact on the affinity of the compounds, with a 1-2 log10 
increase in IC50 values for all the N1 NAs. There were larger differences in the IC50 values with 
and without incubation for the seasonal (H1N1) and the H274Y mutant NAs with both 5 and 6, 
indicating slower binding compared to some of the other compounds. Except for the clade 1 
(H5N1) NA the IC50 values continued to decrease with or without preincubation for these two 
compounds. This suggested both 5 and 6 had a slow turnover. 
2.1.2 N2 NA 
IC50 kinetics for the H3N2 and oseltamivir resistant E119V NAs showed loss of the 4-OH 
improved affinity (lower IC50 values) of 3 binding to the wild type H3N2 NA, compared to 2 
although it was still fast, with no significant effect of preincubation on IC50 values (Figure 3A, 
Table 1). While 2 binds with higher affinity to the E119V mutant than to wild type, in contrast 3 
binds with lower affinity to the mutant NA. 
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Loss of the 7-OH improved affinity, with lower IC50 values for 4 than for 2 for both the wild type 
and E119V mutant NAs.  As seen for 2, compound 4 bound with higher affinity to the mutant 
NA, and it also showed slower binding than to the wild type NA. 
While loss of either the 8-OH or 9-OH resulted in significantly reduced affinity, IC50 values were 
similar for each of the compounds for both the wild type and E119V mutant. Compound 5 
showed the classic slow binding profile for both wild type and E119V NAs, with about a 10-fold 
decrease in IC50 values after preincubation, and slow dissociation, with a small increase in IC50 
values with time after addition of substrate. Compound 6 showed the unusual profile, similar to 
the seasonal (H1N1), with the IC50 values continuing to decrease with or without preincubation 
(Figure 3, Table 1, Supporting information Table S1). 
2.1.3 N9 NA 
The G70C H1N9 reassortant was used to evaluate inhibition of the N9 NA, as a model for the N9 
NA of the pathogenic (H7N9) viruses recently spreading in China.25, 26  Compound 2 was fast 
binding to the wild type N9 NA. Although the IC50 values were comparable between the E119G 
mutant and wild type NAs (Figure 3B, Table 1 and Supporting information Table S2) the bar 
graph profiles showed the IC50 values decreased with or without preincubation for the E119G 
mutant NA, suggesting slower turnover.  In contrast to 2, compound 3 demonstrated higher 
affinity, but slower binding to the wild type N9 NA (Figure 3B, Table 1). While the E119G 
mutant showed the classic resistance profile of higher IC50 values, fast binding and dissociation, 
with IC50 values increasing with or without preincubation, as seen for this mutant with 
zanamivir16 (Table 1, Supporting information Tables S1, S2), the loss of the 4-OH did not affect 
the affinity of binding to this mutant NA compared to 2.  It did however decrease binding of 3 
compared to the wild type N9 NA (Supporting information Table S2). 
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Compared to 2, loss of the 7-OH led to a higher affinity of 4 for the wild type N9 NA. In 
contrast, while 4 had reduced binding to the E119G NA compared to the wild type (Supporting 
information Table S2), loss of the 7-OH had no impact on binding to this mutant NA compared 
to 2. (Supporting information Table S1).  
Both 5 and 6 demonstrated a further decrease in IC50 values with or without preincubation over 
the 60 min reaction time, indicating slow turnover. As seen for all the other viruses the loss of 
either the 8-OH or the 9-OH reduced their affinity. The E119G substitution also reduced binding 
of both inhibitors, compared to the wild type NA and compared to 2 (Supporting information, 
Table S2). This reinforces the importance of both the 8- and 9-OH groups for high affinity 
binding. It further highlights the complex interactions involved in ligand binding, since the 8- 
and 9-OH groups are on the opposite side of the active site, compared to E/G119.  
2.1.4 B NA 
The B/Perth viruses were used to evaluate efficacy against wild type and broadly NAI resistant 
influenza B NAs. The D197E mutation results in reduced affinity and faster dissociation of 1 
(Figure 3C, Table 1, Supporting information Table S1), and because the D197E substitution 
affects interaction of R152 with the N-acetyl group on the sugar ring, it would be expected to 
affect binding of all sialic acid based inhibitors.  
Compared to 2, loss of the 4-OH, as with the influenza A NAs, led to higher affinity of 3 (Figure 
3C). Unexpectedly 3 bound with similar affinity to both the wild type and E197 mutant NA, 
somehow compensating for the reduced binding due to the altered E197/R152 interactions with 
the N-acetyl group (Figure 3C, Supporting information Table S2). Both showed the classic slow 
binding profile, with IC50 values after preincubation being lower than without preincubation 
(Figure 3C, Table 1). 
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Compounds 4, 5 and 6 all had reduced affinity (higher IC50 values) for the mutant NA compared 
to the wild type NA, (Supporting information Table S2). However, unlike 1, compounds 2-6 still 
demonstrated slow binding to the B/Perth wild type and mutant NA (Table 1 and Supporting 
information Table S1).  
Loss of the 7-OH resulted in a marginally higher affinity compared to 2 (Table 1), but loss of the 
8- or 9-OH groups again reduced affinity of 5 and 6 for both wild type and the D197E NAs, 
while maintaining the slow binding, and slow dissociation seen with other viruses (Table 1, 
Supporting information Table S1). 
With the NAIs the ratio of -/+ preincubation has been a good indicator of slow and fast binding. 
However, for compounds 5 and 6 the -/+ ratios in Table 1 clearly do not fully reflect what 
appears to be slow turnover, since the IC50 values continue to decrease after preincubation 
indicating additional compound is still binding. This demonstrates the importance of looking at 
the profiles of the IC50 kinetics graphs, demonstrating the changes in IC50 values over time, rather 
than a single IC50 value or -/+ ratio.  
2.2. Reactivation  
While our IC50 kinetics assays give an indication of the relative rate of dissociation after the 
addition of substrate in the preincubation reaction (Supporting information Table S1), this is still 
in the presence of inhibitor. The classic reactivation experiments react purified NAs or viruses 
with excess inhibitor, then remove the unbound inhibitor by spin columns and monitor recovery 
of enzyme activity after addition of substrate.8, 18, 27-29 However this requires significant 
quantities of virus or NA and is labor intensive. We had also seen a different pattern for the IC50 
kinetics especially for compounds 5 and 6 than previously seen with other NAIs binding to wild 
type virus NAs, where although preincubation did not lead to obvious enhanced binding, the IC50 
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values continued to decrease either with or without preincubation. We therefore used our 96-well 
solid phase reactivation assay19, 24 to test dissociation of 2-6 from the wild type virus NAs as a 
further confirmatory assay to determine whether the novel profiles for 5 and 6 did reflect very 
slow dissociation compared to 2-4. The relative rate of reactivation is expressed as a T½ which is 
the time required for reaching half the maximum average rate of the uninhibited control. Results 
are shown in Table 2. The T½ results for each virus and inhibitor were compared to the T½ for 
the virus controls without inhibitor, by the Student’s t test. Consistent with the IC50 kinetics, 
reactivation was significantly slower for compound 1 for all of the NAs (P <0.001).19 
For the (H1N1) A/Mississippi seasonal strain, reactivation was significantly slower for 2-6, with 
6 being the slowest. 
For the (H1N1)pdm09 and both (H5N1) strains, reactivation after removal of 2 and 3 was very 
rapid, with T½ values barely more than 10 min. In fact, some ultimately showed an enhanced 
rate of MUNANA cleavage compared to the control with no inhibitor. This is consistent with the 
IC50 kinetics showing similar values with or without preincubation. Reactivation after removal of 
3 was marginally faster than reactivation after removal of 4 for each of these viruses, but was not 
significantly faster. Turnover of 5 and 6 were slower, as also seen in the IC50 kinetics, although 
only significantly slower for the (H1N1)pdm09 and (H5N1) clade 2 viruses. 
For the H3N2 NA, in contrast to compound 1, reactivation after removal of compounds 3 and 4 
was very fast, comparable to the control. Reactivation after removal of compound 2 was just 
significantly slower than the control. Turnover of 5 and 6 were significantly slower, again 
consistent with the IC50 kinetics showing decreases in IC50 values in both reactions. 
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For the NWS/G70C N9 NA reactivation was very rapid after removal of compounds 2, 3 and 4 
while reactivation after removal of 5 and 6 was significantly slower reflecting the results in the 
IC50 kinetics where the IC50s continued to decrease in the preincubation reaction. 
Reactivation of the B/Perth NA activity after removal of the inhibitors was slowest of all of the 
inhibitors 2-6, even slower than for 1. Results were consistent with the IC50 kinetics, with 3 
having the fastest turnover of all the deoxy inhibitors for B/Perth, and 5 and 6 having the slowest 
turnover of any virus NA-DFSA combination. 
2.3. Plaque reduction assay (PRA) 
We have demonstrated in enzyme assays that while the loss of the 4-OH generally leads to lower 
affinity, it results in faster turnover.  In contrast loss of the 8- and 9-OH groups result in lower 
affinity, but slower turnover. Since the ability of the covalent DFSA inhibitors to inhibit virus 
replication will be a combination of the relative affinity as well as their turnover we tested their 
efficacy against a selection of the wild type viruses in the PRA to see whether there was greater 
correlation with the slow turnover of affinity. The EC50 is the effective concentration of inhibitor 
to reduce plaque sizes by 50% compared to the uninhibited control. We tested the 
A/Mississippi/03/01 seasonal (H1N1) virus, the G70C H1N9 reassortant, the B/Perth/211/2001 
virus and two different human H3N2 viruses, A/Fukui/45/04 and A/Victoria/503/06, as some 
H3N2 are known to have lower sensitivity to the other NAIs in cell culture, due to lower affinity 
of their HA. This lowers their dependence on the NA, making them appear less sensitive in a 
PRA, due to the altered HA and NA balance. 
Inhibition of the (H1N1) A/Mississippi virus was comparable for compounds 2, 3 and 4 in the 
PRA (Table 3, Supporting information Figure S1). Despite very slow dissociation of 5 its 
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efficacy was less than that of the other inhibitors, and 6 was the least potent, reflecting the 
relative IC50 values in the enzyme inhibition assays. 
All inhibitors, including 1 showed lower potency against the H3N2 A/Fukui/45/04 (Table 3) 
virus in the PRA compared to the other viruses. This is likely due to the HA having a lower 
affinity for the sialic acid receptor, hence less NA activity is needed for virus to elute and 
spread.30 Although the IC50 values in the enzyme assay were lower for compounds 3 and 4 
compared to compound 2, there was no difference detectable in their potency in the PRA. 
Inhibition by 5 was even poorer, reflecting its lower efficacy in the enzyme assay, as we saw no 
inhibition even at 100 µM in the PRA.  
Since the A/Victoria/503/06 H3N2 virus was more sensitive to zanamivir in the PRA, we also 
tested this virus with the DFSA panel. Both 3 and 4 showed higher potency compared to DFSA 
2, with lower efficacy of 5 and 6 (Table 3). This is consistent with the enzyme assay results seen 
with the A/Fukui/45/04 N2 NA. 
All the inhibitors were mostly more potent against the B/Perth virus in the PRA than against the 
other influenza A viruses tested (Table 3), which was also observed in the IC50 kinetics assays. 
Once again, although 2, 3 and 4 had faster turnover compared to 5 and 6, they were more potent 
than 5 and 6 with their slower turnover. 
Thus, it appears that efficacy of inhibition of virus replication in cell culture primarily reflects 
the affinity of the compound for the NA, rather than the turnover rate. 
 
2.4. X-ray crystal structures 
2.4.1 Trapped intermediates in the active site 
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As seen previously with DFSA, 29 binding of the deoxy compounds 3-6 resulted in the trapping 
of intermediates in the N9 NA. There is a clear rotation of the COOH group and loss of the 
fluorine (F2) at the C2 positon of the ligand. The ligands were trapped in the form of the two n-
deoxy (n=4,7,8,9) 3-fluorosialyl-enzyme intermediates bound in the active site (Figure 4). A 
covalent bond of ~1.4 Å was observed in the electron density map between C2 of n-deoxy 
(n=4,7,8,9) 3-fluoro sialic acid and the phenolic oxygen of Y406 (Figure 4) consistent with 
previous results recently reported.8 A covalent bond has also been observed previously in the 
structures of the bacterial GH33 sialidase NanI31, N2 NA with a DFSA32 and N9 NA with a 
DFSA derivative 3-equatorial-2,3-difluoro-4-guanidino sialic acid (FeqGuDFSA).8  
Again, similar to the 2-NA N9 complex9 in addition to the covalent intermediate species 
detected, we also identified non-bonded species which we assumed to be unsaturated forms of n-
deoxy 3-fluoro sialic acid intermediates with fractional occupancies: 20% / 80% (3), 45% / 55% 
(4), 60% / 40% (5), and 25% / 75% (6), respectively for covalently bonded and non-bonded 
species, (Figure 4A, C, E, G). 
The distances between the anomeric C2 of non-bonded forms and the phenolic oxygen of Y406 
are ~2.5 Å, much longer than the corresponding C-O covalent bond lengths observed for the 
covalent intermediates. This non-bonded form of the -n-deoxy fluorosialic acid intermediates is 
consistent with an oxocarbenium ion like transition state in which the carboxylate group is 
coplanar with the oxocarbenium ion plane with considerable sp2 hybridization at the anomeric 
carbon. The oxocarbenium ion positive charge at the ring oxygen O6 is stabilized by hydrogen 
bonds with waters at 2.7-3.4 Å in all N9 complexes. The oxocarbenium ion is thus sandwiched 
between the active site negatively charged residues, in particular the deprotonated tyrosine and 
waters. Further, the oxocarbenium ion is also stabilized by electrostatic interactions with the 
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negatively charged carboxylate group adjacent to the anomeric carbon C2 and the fluorine 
attached to the C3 carbon. These anionic charges assist with the departure of the negatively 
charged fluorine leaving group and the formation of a covalent intermediate bound to the 
phenolic oxygen of tyrosine. Because the oxocarbenium ion has double-bond character between 
the anomeric carbon C2 and the ring oxygen O6, this part of the structure must be planar. Thus, 
for a 6-membered ring, C2, O6, C1 and C3 must lie in a plane. This arrangement can be 
accommodated in a 6-membered ring only in the half chair conformation similar to a glycal 
DANA generated at a low rate from sialic acid soaked in crystals of the influenza B virus NA at 
4oC for an extended time.33 Similarly, the n-deoxy-DFSA fluorinated substrate analogues 
facilitated trapping enzyme bound species resembling intermediates or “transition states”. The 
structures of assumed bonded and non-bonded ligands were refined from the observed 
experimental electron density with stereochemical constraints.  The ligands are stabilized by an 
extended hydrogen bond network involving residues and structured water molecules, most of 
them are well documented in the NA structures with sialic acid1 and FeqGuDFSA.8 In addition, 
the fluorines make contacts in the range of 3.0-3.9 Å with the side chain nitrogen atom of R118 
as well as short contacts in the range of 2.5-3.5 Å with the carboxyl oxygen of D151. Interactions 
between fluorine and a protonated nitrogen are well known and have been computed at up to 
13.5 kcal/mol.8 
2.4.2 Ligands in additional receptor binding sites 
The omit34 electron density (Figure 4B, D, F, H) revealed one additional n-deoxy-DFSA 
(n=4,7,8,9) site formed by three serines: S367, S370 and S372 (N2 numbering used throughout). 
This is the known second site in the N9 NA, previously reported to bind sialic acid, which is 
discrete from the catalytic site.35 The n-deoxy-DFSA position is overlapping well with that for 29 
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and sialic acid in this second binding site35 confirming that the secondary ligand sites in N9 NA 
are not specific to the sialic acid complex only. 
2.4.3 Compound 3 
The secondary receptor binding site confirms the original structure of 3 (Figure 4B), prior to 
binding and cleavage. According to kinetic assays above 3 binds with higher affinity than 2 to 
the wild type N9 (Figure 3, Table 1). While the N9 E119G mutant NA has reduced binding of 3 
compared to the wild type, binding is similar to 2, but shows a different kinetics profile 
suggesting a faster turnover (Figure 3). E119 must provide important interactions, which are lost 
with G119. This is most likely contacts of ~3 Å between the carboxyl groups of E119 and D151 
and the F3 fluorines (Figure 4A). In the case of the wild type N9, the negatively charged 4-OH 
group next to the electronegative F3 seems to destabilize the F3 contacts with E119 and D151 
and the loss of 4-OH improves binding of 3. 
2.4.4 Compound 4 
The crystal structure shows the second site (Figure 4D), again confirming the original 4 structure 
prior to cleavage. The 7-OH group was mainly involved in contacts of ~2.5 Å with two waters as 
seen in 29 and 3 complexes (Figure4A). Loss of the 7-OH with those water contacts (Figure 4C) 
would be expected to lead to minor changes in affinity to both the wild N9 and its E119G 
mutant. In fact, 4 binds with slightly higher affinity to the wild type than 2, and loss of the 7-OH 
has no impact on binding to the mutant G119 NA compared to 2. 
2.4.5 Compound 5 
In contrast to 3 and 4 N9 complexes, which were obtained by a short soak in ligands, we could 
only obtain complexes for 5 and 6 by co-crystallization. The secondary ligand site in the co-
crystallized 5-N9 complex showed fragmented electron density (Figure 4F), suggesting 
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fractional population of this site and reduced binding affinity. Also, in the active site (Figure 4E), 
8-OH forms important contacts of 2.5-3.5 Å with COOH groups of E276 and E277, of 3.6 Å 
with R292 and of ~3Å with a water. Due to loss of the 8-OH there is an upwards displacement of 
the sugar ring of the ligand to the Y406, but there is also some rotation of both the E276 and 
E277 compared to other complexes.  
2.4.6 Compound 6 
Similar to 5, the complex with 6 was only obtained by co-crystallization and showed high atomic 
displacement parameters and fragmented electron density for 6 in the secondary ligand binding 
site (Figure 4H). This again suggests slower binding and reduced affinity as seen for 5. The 
active site shows (Figure 4G) loss of contacts between 9-OH and E276 (2.5 Å), R224 (3.3 Å), 
and a water (2.8 Å). Loss of these important contacts would correlate with the reduced binding 
affinity of 5 and 6 to not only the N9 but to all other NAs tested. 
 
3. Discussion  
Zanamivir (1) is reported to be a competitive, slow binding inhibitor of the influenza NAs. It has 
been suggested that the 4-guanidino side chain in 1 needs to displace water for high affinity 
binding, hence leading to slow binding.20, 36 Without a guanidino substitution at the 4-position, as 
in 2-deoxy-2,3-didehydro-N-acetylneuraminic acid (DANA) and the 4-amino derivatives of 
sialic acid, binding to the NA is rapid.16 Binding of 2 to influenza NAs would thus be expected to 
be rapid. The aim with a covalent inhibitor is to have high affinity binding, but additionally a 
slower turnover, since unlike competitive inhibitors, once a covalent inhibitor is hydrolyzed it 
cannot inhibit another NA.8 We were interested in testing the impact of removal of one of each 
of the 4, 7-. 8- or 9-OH from 2 on binding affinity (inactivation), and dissociation/turnover 
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(reactivation) with a variety of different wild type and mutant N1, N2, N9 and influenza B NAs. 
Insight into the roles of each of the OH groups could provide important information on potential 
sites for substitution to enhance potency of the DFSA inhibitors, as well as understanding how 
ligand modifications affect binding to known NAI resistant mutants. 
 
Our previous development of microtiter based assays has enabled us to test a large number of 
combinations of inhibitors and wild type and mutant viruses for their relative potency and 
kinetics of binding and dissociation in enzyme assays.11, 15, 16, 19, 23, 24, 37 We observed much more 
variation in affinity and binding kinetics of 2 and 3-6 among different wild type viruses 
compared to 1, oseltamivir and peramivir.16 We showed here that while binding of 2 and some of 
the deoxy derivatives did not show the classic profile of slow binding inhibitors in the IC50 
kinetics reaction to all the tested influenza A NAs, some also did demonstrate slow binding. 
Unexpectedly they all showed slow binding to not only the influenza B wild type NA, but also to 
the mutant influenza B NA. Additionally, in contrast to other NAIs where potency against 
influenza B is generally lower than to influenza A NAs, 2 and its deoxygenated derivatives 3-6 
generally bound with higher affinity to the B/Perth NA, compared to influenza A NAs. This is 
consistent with our previous observations that 2 and its 4-amino and 4-guanidino derivatives 
bound with high affinity to influenza B NA.8 
We have previously shown that mutations which confer reduced susceptibility to the NAIs , 
result in loss of slow binding, so that preincubation makes no difference,11, 15, 16, 37 and inhibitors 
dissociate rapidly.19 However while some of the deoxy DFSA inhibitors did show slow binding, 
and they had reduced affinity for mutant NAs compared to their wild type parent, many still 
showed either slow binding or slow turnover in the mutant NAs. Some of the mutant NAs even 
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bound the compound with higher affinity compared to the wild type NA. Thus, the mutations had 
minimal impact on binding 3-6, compared to 2. 
In general, the loss of the 4-OH resulted in higher affinity binding (lower IC50 values) compared 
to 2 for wild type NAs, while the loss of the 8- and 9-OH resulted in lower affinity, but slower 
binding and turnover. We have previously determined that if the IC50 after preincubation (+) is 
lower than without preincubation (-), then the inhibitor is slow binding (-/+ ratio >1.5-2). 
However, here we observed a novel profile in the IC50 kinetics particularly for 5 and 6, where 
with or without preincubation the IC50 values continued to decrease during the 60 min reaction 
time. This suggested a nett slower binding and dissociation, hence a slower turnover, which was 
not necessarily reflected by the -/+ ratio. This emphasizes the importance of looking at the 
graphs for the whole reaction time and not just a single IC50. This interpretation was supported 
by the results of our reactivation assays, which demonstrated a slower reactivation than for the 
other compounds. We have only observed this unusual pattern of binding with 1 binding to an 
NAI resistant seasonal (H1N1) with a novel Y155H mutation.15  
Additionally, we evaluated the inhibitors in a plaque reduction assay in cell culture, providing 
information on the nett effect of affinity and turnover on inhibition of virus replication and the 
importance of each OH group. While theoretically the inhibitor with the slowest turnover might 
be expected to have the highest nett potency in terms of inhibition of virus replication in vivo, 
this was not the case. Potency was more a reflection of the relative affinity, rather than the 
turnover. Both 5 and 6 which had the slowest turnover of all the compounds, had both the lowest 
affinity and the lowest potency. Conversely, 3 which had a rapid turnover, but higher affinity, 
was more potent than 5 and 6. Thus, our studies have importantly demonstrated that slowing 
down turnover of these mechanism based inhibitors will not necessarily result in higher potency. 
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Structural analysis also supported the observed variation in ligand binding, showing the 
importance of water molecules in stabilizing ligands in the active site as well as the interactions 
of the 8-OH and 9-OH with E276/E277/R224/R292. X-ray crystallography demonstrated that 
like 29 compounds 3-6 could also bind in the second sialic acid binding site.35 This is a non-
catalytic site and the biological role of this site is yet not understood. The NAIs do not bind this 
site, since they have a DANA boat-like conformation. Only ligands with the sialic acid chair 
conformation can bind, in a similar way to binding to the HA.9 One study has shown that the 
ability of NA to bind red blood cells via this second site correlated with the cleavage efficiencies 
of other multivalent substrates.38 Others have more recently shown that substrate binding via the 
second sialic acid-binding site in (H7N9) viruses enhances NA catalytic efficiency against the 
same substrate.39 Hence binding in this site may affect affinity of the DFSA inhibitors, but not 
the kinetics. Thus an inhibitor which can bind both in the secondary sialic acid binding site as 
well as the NA active site, might have advantages in reducing virus binding and spread, 
particularly for avian viruses which continue to pose a pandemic threat.  
 
4. Conclusions 
Although the efficacy of covalent inhibitors is dependent on both the affinity and turnover, we 
have shown here that with the deoxy-DFSA inhibitors 3-6, the advantages of a slower turnover 
can be counteracted by lower affinity. Hence the design of covalent inhibitors needs to 
incorporate modifications leading to both high affinity and slow turnover. Loss of the 8-OH and 
9-OH had the greatest impact on binding and affinity of the covalent inhibitors tested here. 
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Experimental Section 
Materials 
Zanamivir 1 was kindly provided by GSK (Stevenage, UK) and compound 2 was kindly 
provided by the group of Prof. Steve Withers (Vancouver, BC). Compounds 3-6 were prepared 
as previously described.10 The purity of final compounds was ≥95%. Purity was determined by 
elemental analysis and is available in the Supporting Information. 
Viruses and cells 
The following wild type and drug resistant viruses were grown in cell culture as previously 
described.8, 16: B/Perth/211/2001 wild type and D197E cross-resistant mutant,40 
A/Mississippi/03/01 seasonal (H1N1) and H274Y oseltamivir and peramivir resistant mutant,7 
A/Fukui/45/04 H3N2 wild type and E119V oseltamivir resistant mutant,17 A/Victoria/503/06 
H3N2 grown in MDCK cells,41 NWS/G70C H1N9 and E119G zanamivir and peramivir resistant 
mutant.13, 42 The following irradiated viruses were provided by the CSIRO Australian Animal 
Health Laboratory for enzyme assays only (H1N1)pdm09 A/California/7/09 and 
A/Swine/Shepparton/6/2009, and A/Chicken//Vietnam/08/2004 (H5N1) clade 1and 
A/Chicken/Bangli/BBVD-563/2007clade 2 (H5N1).37 
Plaque reduction assays (PRAs) in Madin Darby Canine Kidney cells (MDCK) were carried out 
as previously described8, 23 using an overlay of DMEM/ F12 in 0.5% immunodiffusion-grade 
agarose (MP Biomedicals, Australia), containing 1 mg/mL L-1-tosylamido-2-phenylethyl 
chloromethyl ketone (‘TPCK’)-treated trypsin (Worthington, USA). Serial ten-fold dilutions of 
inhibitors were incorporated into the overlay23 and cells were fixed at 3 days with 1% formalin, 
and stained with 0.05% neutral red and scanned. The EC50 is the effective inhibitor concentration 
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causing a 50% decrease in plaque size. Where there was greater than 50% reduction in plaque 
size between two drug concentrations a range was used. 
 
Enzyme assays 
NA enzyme activity was measured using the fluorescent substrate 4-Methylumbelliferyl N-
acetyl-α-D-neuraminic acid (MUNANA, Carbosynth, Berkshire, UK). MUNANA was diluted to 
a final concentration of 100 µM in 50 mM sodium acetate pH 5.5 and 5 mM CaCl2. We used a 
BMG FLUOstar Optima reader and the kinetics function for real time monitoring of the 
fluorescent signals. Fluorescence was read using excitation and emission filters 355 and 460 nm 
respectively.  
All viruses were initially titrated to determine a dilution which gave similar NA enzyme activity. 
Inhibition assays were carried out using the constant amount of each virus, incubated with seven 
serial 10-fold dilutions of each inhibitor. Inhibitor concentrations ranged from 0.01 nM to 10 
mM depending on the compound, with the lowest range for compound 1 only. The eighth well 
contained virus only as the uninhibited control. Graphs of concentration of inhibitor versus % 
inhibition of enzyme activity compared to the uninhibited control were plotted in Sigmaplot.  
The IC50 values were determined as the concentration of inhibitor which reduced the enzyme 
activity by 50% compared to the control.   
While the IC50 for NAIs is routinely calculated for a single time point after the addition of 
MUNANA, (usually 60 min), because the NAs are described as time dependent, or slow binding 
inhibitors,20, 21 we have previously shown that the IC50 changes during the reaction time, and is 
dependent upon whether the virus is preincubated with inhibitor, or not.11, 16, 23 Based on this 
observation we developed an IC50 kinetics enzyme inhibition 
11, 16, 23 assay which has provided 
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information on the relative rates of inhibitor binding, and the relative rates of dissociation of 
many different wild type and mutant viruses and NAIs.11, 15, 16, 23, 24, 37 For IC50 kinetics two 
separate inhibition assays were carried out.  In the first reaction virus was preincubated with 
serial 10-fold dilutions of inhibitor for 30 min at room temperature, prior to the addition of 
substrate, and in the second reaction virus, serial 10-fold dilutions of inhibitor and MUNANA 
substrate were all co-incubated. Fluorescence was read every minute for 60 min and the percent 
inhibition of enzyme activity for each 10 min time point compared to the uninhibited control was 
plotted against the concentration of inhibitor. The IC50 values were determined for each 10 min, 
hence 6 inhibition curves and 6 IC50 values were calculated for each reaction. Each virus-
inhibitor combination was tested in duplicate for each of the pre incubation and no preincubation 
reactions. IC50 values were calculated independently for each 10 min time point for each of the 
duplicates and the mean IC50 values were then plotted as bar graphs to demonstrate the changes 
in IC50 with time i.e. the IC50 kinetics.  
Solid phase reactivation assays were carried out as recently described.19, 24 Briefly, after binding 
virus to multiple wells in a black ELISA plate (Greiner Fluorotrack 600), inhibitor was added at 
>10 times the IC50 and incubated for 30 min. Inhibitor was then washed off, MUNANA substrate 
was added, and the reactivation of enzyme activity was monitored after each 10 min for 4 hours. 
The relative rates of activity were calculated compared to the uninhibited virus control for each 
30 min period, and if reactivation was rapid, rates for the initial 10 and 20 min were calculated. 
The T½ was calculated as the time taken for the rate to reach half the maximum rate of the 
control.19 Two or three wells for each drug were used per assay in two independent assays. 
 
Statistics 
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Data for reactivation assays were analyzed for statistical significance using a Student’s t test, 
where a P value of <0.05 was considered statistically significant. 
 
Crystallization 
NA from influenza virus A/NWS/Tern/Australia/G70C/75 was purified as described previously13 
and crystallized in potassium phosphate buffer (1.7 M, pH 6.7) as previously described.35 The 
N9-NA 3 and 4 complexes were prepared by soaking crystals in cryo-protectant solution 
containing crystallization well solution plus 20% glycerol and 2 mM concentration of inhibitor 
for 30 min at ambient temperature and 15 min at 4oC, respectively. The N9-NA 5 and 6 
complexes were prepared by co-crystallization. 
 
X-ray data collection, structure determination, and refinement 
X-ray diffraction data sets for single crystals of N9 NA with inhibitor complexes in well solution 
plus 15% (v/v) glycerol as cryo-protectant were collected at -173°C with 360o rotation, 1o 
oscillation and 1s exposure with wavelength of ~0.95 Å using the MX1/MX2 beamlines at the 
Australian synchrotron.  The data sets were processed with HKL2000.43 Further data collection 
statistics are given in Table 4. The positions of one N9 NA molecule were identified in the 
asymmetric units by PHASER 44 molecular replacement using the structure of N9 (PDB entry: 
1NNC)35 without ligands. The structures with protein molecules alone were refined and then the 
inhibitors were built into the observed residual electron densities. 
Initial refinement of the inhibitor position did not account for all the residual density observed in 
all N9 NA protein structures. In particular, there was slight negative residual density around the 
F3 atom and positive residual density in the region between the inhibitor and the Y406 (N9 NA) 
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residue. The continuous bridge of residual electron density between the C2 atom of the inhibitor 
and hydroxyl oxygen of the aromatic side chain of Y406 residue suggested the C-O covalent 
bond, however the refined bond distance was always longer than the expected covalent bond of 
~1.4Å. Next, the covalent intermediate species accompanied by unsaturated forms of fluorosialic 
acid as oxocarbenium ion transition-state analogues were refined in N9 NA protein structures. 
The geometry of unsaturated forms of fluorosialic acid species is similar to that of DANA in 
which the carboxylate group is coplanar with the ring plane with considerable sp2 hybridization 
at the anomeric carbon. Since a fluorine atom is refined at the chiral position, the double bond is 
between the ring oxygen and the anomeric carbon, with positive charge at the oxygen resembling 
an oxocarbenium ion transition state. Adjusting the occupancies of two bonded and non-bonded 
conformations the length of the covalent linkage for bonded species was refined to a chemically 
sensible value of ~1.4 Å. After that the corresponding LINK record was added to the PDB files 
to define this bond. The occupancies of two conformations were refined to 20% / 80% (3), 45% / 
55% (4), 60% / 40% (5), and 25% / 75% (6) respectively for covalently bonded and non-bonded 
species. The refinement of occupancy was carried iteratively alternating fixed B-factors or 
occupancies until physically meaningful and similar for both species values of atomic B-factors 
were obtained.  
In addition, the secondary binding site for molecules of all deoxy-DFSA were identified in the 
N9 NA complexes, by difference Fourier methods during the course of the refinement. It should 
be noted that both soaking and co-crystallization were sufficient to observe the initial binding 
events of 2 including secondary sites and a variable mixed occupancy of the active site. Electron 
densities for secondary sites of co-crystallized complexes of 5 and 6 were less defined and 
somewhat fragmented.  
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Water molecules in the active site and elsewhere were then added. Iterative refinement and 
model building were conducted using REFMAC45 and XFIT/MIFit.46, 47 N-linked glycans were 
observed at all predicted sites (N86, N146 and N201) and are included in the refined atomic 
model. Refinement yielded a model for 388 residues for the N9 with 11 attached glycans, 1 
calcium ion, two alternating conformations of the inhibitor, 1 n-deoxy DFSA molecule at 
additional site and 430 (3), 423 (4), 483 (5), and 354 (6) water molecules (Table 4). Progress of 
the refinement was monitored using the Rfree statistics based on a test set encompassing 5% of 
the observed diffraction amplitudes.48 The coordinates of the complexes have been deposited in 
the PDB. Deposition codes and further experimental and data processing details are given in 
Table 4. Final omit electron densities associated with the ligands in active site and secondary 
binding sites are displayed in Figure 4 for all N9 NA – inhibitor complexes. 
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Table 1 Comparison of 60 min IC50 values with (+) and without (-) preincubation  
 
µM  
sH1N1 
wt 
sH1N1 
H274Y 
pdmH1N1 
Cal 
pdmH1N1 
Shep 
H5N1  
Cl 1 
H5N1  
Cl 2 H3N2 wt 
H3N2 
E119V 
H1N9 
wt 
H1N9 
E119G B wt 
B 
D197E 
1- 0.0078 0.0060 0.0120 0.0058 0.0120 0.0112 0.0324 0.0519 0.0057 0.8159 0.1674 0.4338 
1+ 0.0019 0.0022 0.0011 0.0014 0.0025 0.0013 0.0038 0.0034 0.0027 0.6784 0.0089 0.2575 
-/+ 4.09 2.72 10.85 4.23 4.71 8.62 8.53 15.26 2.10 1.20 18.81 1.68 
2- 0.116 0.139 0.791 0.791 2.168 0.889 1.665 0.465 1.103 1.201 0.414 1.257 
2+ 0.080 0.116 0.601 0.470 1.662 0.863 1.377 0.238 1.192 1.148 0.065 0.174 
-/+ 1.45 1.19 1.32 1.68 1.30 1.03 1.21 1.95 0.93 1.05 6.37 7.23 
3- 0.048 0.024 0.428 0.474 0.985 0.535 0.313 3.705 0.119 1.278 0.076 0.250 
3+ 0.069 0.133 0.490 0.490 1.396 0.583 0.318 3.675 0.011 1.050 0.027 0.032 
-/+ 0.69 0.18 0.87 0.97 0.71 0.92 0.98 1.01 11.23 1.22 2.79 7.75 
4- 0.061 0.098 0.457 0.418 0.460 0.281 0.472 0.191 0.438 0.985 0.228 1.550 
4+ 0.037 0.104d 0.330 0.316 0.710 0.316 0.345 0.102 0.289 0.874d 0.040 0.212 
-/+ 1.65 0.95 1.39 1.32 0.65 0.89 1.37 1.88 1.51 1.13 5.76 7.30 
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5- 8.29 1.15 25.81 25.77 21.66 28.20 28.70 25.14 23.02 132.55 7.62 40.05 
5+ 2.61 0.28 22.35d 21.96d 17.05 24.52d 5.01 4.40 10.91d 107.87d 1.15 14.48d 
-/+ 3.17 4.04 1.15 1.17 1.27 1.15 5.73 5.71 2.11 1.23 6.60 2.77 
6- 10.76 6.42 31.71 29.64 20.68 23.77 44.57 36.26 25.38 234.81 9.19 79.03 
6+ 4.50d 4.69d 20.96 20.68 25.40 26.10 29.51d 25.99d 22.24d 210.19d 4.48d 32.23d 
-/+ 2.39 1.37 1.51 1.43 0.81 0.91 1.51 1.40 1.14 1.12 2.05 2.45 
The IC50 values are the means of two individual IC50 values for each virus-inhibitor combination.  
a Virus abbreviations: sH1N1=A/Mississippi/03/01 seasonal (H1N1), pdmH1N1 Cal =pandemic H1N1 A/California/7/09 H1N1, pdmH1N1 
Shep =pandemic H1N1 A/Swine/Shepparton/6/2009, H5N1 Cl 1=A/Chicken/Vietnam/08/2004 (H5N1) clade 1, H5N1 Cl 2= 
A/Chicken/Bangli/BBVD-563/2007 (H5N1)clade 2, H3N2=A/Fukui/45/04 (H3N2) , H1N9=NWS/G70C H1N9, B=B/Perth/211/2001 
b - = no preincubation, + = preincubated for 30 min prior to addition of MUNANA substrate,  
c The greater the difference between no preincubation and preincubation the slower the binding, -/+ ~1 indicates fast, >1.5-2 indicates slow 
binding. 
d IC50s continue to decrease both with and without preincubation (Figures 1 and 2), so the ratio may not properly reflect the extent of slow 
binding.   
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Table 2 Time (T½ min) for reaction rates to reach 50% of the maximum rate of the uninhibited control after removal of inhibitor 
Results are from at least two independent assays, with ≥2 replicates per assay.  
a Virus abbreviations: A/Mississippi =A/Mississippi/03/01 seasonal (H1N1), pdmH1N1 A/Shep =pandemic H1N1 A/Swine/Shepparton/6/2009, 
H5N1 Clade 1=A/Chicken/Vietnam/08/2004, H5N1 Clade 2= A/Chicken/Bangli/BBVD-563/2007, H3N2 A/Fukui =A/Fukui/45/04 (H3N2), 
H1N9 G70C=NWS/G70C H1N9, B/Perth=B/Perth/211/2001.  
Virus  Control 1 19 2 3  4  5   6  
 Ave (SD)  Ave (SD) Ave (SD)  Ave (SD) Ave (SD) Ave (SD) Ave (SD) 
H1N1 A/Mississippi 15.6 (6.3) 41.3 (7.7)b *** 24.8 (2.3)* 26.7 (0.4)* 29.2 (1.6)** 30.4 (9.0)** 37.5 (4.4)*** 
pdmH1N1 A/Shep 12.5 (3.1) ND 11.8 (1.6) 11.6 (1.8) 15.8 (0.4) 17.8 (3.7)** 24.5 (3.5)*** 
H5N1 Clade 1 15.6 (3.7) 27.7 (2.7)*** 12.0 (1.1) 13.7 (1.0) 15.0 (2.7) 19.4 (5.5) 17.2 (3.5) 
H5N1 Clade 2 12.1 (1.0) 72.8 (5.1)*** 8.5 (0.5) 10.6 (2.5) 12.3 (2.0) 23.6 (7.7)*** 16.9 (3.3)** 
H3N2 A/Fukui 12.8 (3.5) 108.7 (18.8)*** 17.6 (2.1)* 13.4 (4.0) 13.9 (3.8) 25.1 (2.9)*** 29.7 (7.2)*** 
H1N9 G70C 10.9 (2.1) 32.1 (1.6)*** 11.1 (0.8) 12.0 (1.1) 13.5 (0.8) 32.2 (1.0)**** 30.6 (0.6)*** 
B/Perth 10.5 (2.2) 24.6 (3.5)*** 43.6 (4.2)*** 29.2 (4.8)*** 68.7 (14.5)*** 185.5 (31.9)*** >240*** 
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b The T½ value for each inhibitor was compared to the control values by the Student’s t test, significantly slower compared to control *=P <0.05, 
** P <0.01, *** P <0.001 
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Table 3 EC50s of compounds causing a 50% reduction in plaque size 
 
Virus 1 
nM 
 2 
µM  
3 
µM  
4 
µM  
5 
µM  
6 
µM  
H1N1 A/Mississippi  ≤1   1  1  0.1-1  10  10-100  
H3N2 A/Fukui  100   100  100  10-100  ≥100  ND 
H3N2 MDCK A/Victoria  0.1-1   100  10  10  ≥100  ≥100  
H1N9 G70C  1-10   1-10  1-10  10  100  100  
B/Perth 10   1  1  1-10  10-100  10-100  
        
A/Mississippi =A/Mississippi/03/01 seasonal (H1N1), H3N2 A/Fukui =A/Fukui/45/04 (H3N2), 
A/Victoria =A/Victoria/503/06, H1N9 G70C=NWS/G70C H1N9, B/Perth=B/Perth/211/2001. 
Results are from two independent assays.   
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Table 4.  
X-ray data collection and refinement statistics. 
 N9 NA -3 N9 NA -4 N9 NA -5 N9 NA -6  
PDB entry   5W26 5W2U 5W2W 5W2Y  
Wavelength (Å) 0.95324 0.95369 0.95324 0.95373  
Resolution range (Å) 42.00 – 1.90 
(1.95 – 1.90)a 
48.38 – 2.00 
(2.05 – 2.00) 
48.30 – 1.85 
(1.90 – 1.85) 
48.48 – 2.39 
 (2.45 – 2.39) 
 
Space group I 4 3 2 I 4 3 2 I 4 3 2 I 4 3 2  
Unit cell  a=b=c=180.94 Å, 
α=β= γ=90o 
a=b=c=180.03 Å, 
α=β= γ=90o 
a=b=c=180.71 Å, 
α=β= γ=90o 
a=b=c=181.38 Å, 
α=β= γ=90o 
 
Unique reflections 37832 (2735) 32364 (1723) 40605 (2158) 19147 (1035)  
Multiplicity 72.0 (25.0) 78.4 (32.0) 75.0 (29.0) 35.4 (16.6)  
Completeness (%) 99.9 (99.9) 99.6 (99.8) 99.8 (99.0) 98.5 (98.2)  
Mean I/σ(I) 39.0 (1.5) 10.0 (1.3) 10.2 (1.2) 11.4 (1.8)  
Wilson B-factor 22.5 23.1 21.8 22.2  
Matthews coefficient, Vm 2.83 2.83 2.83 2.83  
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(Å3/Da) 
Bulk solvent ksol(e/Å
3), Bsol(Å
2) 0.40, 47.9 0.41, 61.5 0.39, 52.3 0.41, 42.9  
Rmerge
b 0.170 (0.750) 0.308 (0.760) 0.297 (0.820) 0.394 (0.762)  
Rwork
d 0.136 (0.289) 0.142 (0.273) 0.140 (0.231) 0.141 (0.257)  
Rfree
e 0.177 (0.294) 0.187 (0.308) 0.171 (0.262) 0.250 (0.274)  
Number of non-hydrogen atoms 3718 3715 3793 3655  
  macromolecules 3090 3094 3087 3094  
  ligands 197 197 222 208  
  water 430 423 483 352  
  metals 1 1 1 1  
Protein residues 388 388 388 388  
RMS(bonds) (Å) 0.020 0.021 0.019 0.017  
RMS(angles) (o) 2.017 2.078 1.997 1.937  
Average B-factor (Å2)  24.0 25.0 24.0 23.0  
Ramachandran favoured (%) 96 96 95 95  
Ramachandran allowed (%) 4 4 5 5  
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aStatistics for the highest-resolution shell are shown in parentheses. bRmerge = ∑hkl∑j |Ij - <Ij>| / ∑hkl∑j | Ij |, where hkl specifies unique indices, j 
indicates equivalent observations of hkl, Ij and σj
2 are the observed intensities and their errors, and <Ij> and <σj> are the mean values.
 d
R = ∑hkl || 
Fo | - Fc | / ∑hkl | Fo|, where | Fo | and | Fc | are the observed and calculated structure factor amplitudes, respectively. 
eRepresents 5% of the data. 
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Figure Legends 
 
Figure 1 
Chemical structures of Zanamivir (1), 2,3-difluoro sialic acid (DFSA) (2), 4-deoxy (3), 7-
deoxy (4), 8-deoxy (5) and 9-deoxy (6) DFSA. 
 
Figure 2  
IC50 Kinetics showing changes in IC50 values during the 60 min reaction period with (+) or 
without preincubation (-) for N1 NAs. The IC50 value for each 10 min time point is the mean 
of the individual IC50 values of the duplicates for that virus-inhibitor reaction. The greater the 
difference in final (60 min) IC50 values between the reactions without and with preincubation 
(-/+ ratio), the slower the binding. Additionally, the rate of increase of the IC50 values after 
preincubation with inhibitor upon addition of MUNANA substrate, gives a qualitative 
indication of the dissociation rate.  The faster the increase, i.e. the greater the difference 
between the 10 min and 60 min IC50 values, the faster the dissociation. IC50 values for 
compounds 5 and 6 continue to decrease for some viruses even after preincubation. This 
novel profile suggests compounds are very slow binding. (A) Seasonal (H1N10 and H274Y 
mutant, which has reduced sensitivity to oseltamivir and peramivir. (B) pdmH1N1 Cal = 
human isolate A/California/7/09, Sh=swine isolate A/Swine/Shepparton/6/2009. (C) H5N1 cl 
1= A/Chicken//Vietnam/08/2004 clade1, cl 2= A/Chicken/Bangli/BBVD-563/2007 clade 2 
 
Figure 3  
IC50 Kinetics showing changes in IC50 values during the 60 min reaction period with (+) or 
without (-) preincubation for N2, N9 and B NAs. The IC50 value for each 10 min time point is 
the mean of the individual IC50 values of the duplicates for that virus-inhibitor reaction. The 
Page 46 of 52
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
47 
 
greater the difference in final (60 min) IC50 values between the reactions without and with 
preincubation (-/+ ratio), the slower the binding. Additionally, the rate of increase of the IC50 
values after preincubation with inhibitor upon addition of MUNANA substrate, gives a 
qualitative indication of the dissociation rate.  The faster the increase, i.e. the greater the 
difference between the 10 min and 60 min IC50 values, the faster the dissociation. IC50 values 
for compounds 5 and 6 continue to decrease for some viruses even after preincubation. This 
novel profile suggests compounds are very slow binding. (A) H3N2 wild type and E119V 
mutant, which has reduced sensitivity to oseltamivir. (B) N9 wild type and E119G mutant, 
which has reduced sensitivity to zanamivir. (C) B/Perth wild type and D197E mutant which 
has reduced sensitivity to all NAIs. 
 
Figure 4 
The N9 NA active site complexes with the trapped covalently bound 3-fluoro-sialyl-enzyme 
intermediate in yellow and non-bonded 3-fluoro-oxocarbenium ‘‘transition-state” analogue in 
green are shown in the left side panels. The n-deoxy-DFSA (n=4,7,8,9) secondary sites are 
shown in purple in the right side panels. Red spheres represent water molecules. (A) and (B) 
compound 3; (C) and (D) compound 4; (E) and (F) compound 5; and (G) and (H) compound 
6, respectively. All sites are overlaid with the omit 34 electron density map shown as a grey 
mesh contoured at 1σ within 1.6 Å of ligands. The figure was produced using PyMol.49  
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Figure 1 
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Figure 2 
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Figure 3 
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